LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Detection and prediction of Streptococcus pneumoniae serotypes directly from nasopharyngeal swabs using PCR.

    Lang, Amanda L S / McNeil, Shelly A / Hatchette, Todd F / Elsherif, May / Martin, Irene / LeBlanc, Jason J

    Journal of medical microbiology

    2015  Volume 64, Issue 8, Page(s) 836–844

    Abstract: Monitoring Streptococcus pneumoniae serotype distribution is important to assess the impact and effectiveness of pneumococcal vaccine programs. With the challenges of Quellung serotyping, PCR-based serotype prediction is increasingly being used for large- ...

    Abstract Monitoring Streptococcus pneumoniae serotype distribution is important to assess the impact and effectiveness of pneumococcal vaccine programs. With the challenges of Quellung serotyping, PCR-based serotype prediction is increasingly being used for large-scale epidemiological studies. This study used real-time (RT)-PCR targeting the genes encoding autolysin (lytA) and capsular biosynthesis gene A (cpsA) of S. pneumoniae in nucleic acids extracted directly from nasopharyngeal (NP) swabs submitted for viral studies. If the specimen was lytA or cpsA PCR-positive, then serotype prediction was performed on the same nucleic acid using eight conventional multiplex PCRs (cmPCRs) and seven real-time multiplex PCRs (rmPCRs). Of 1770 NP swabs, 132 (7.5  %) were lytA-positive and 122 (6.9  %) were positive for both targets (lytA and cpsA). Of the 122 lytA(+)cpsA(+) specimens, a serotype could be assigned in 52 (41.8  %) using cmPCR alone and the yield was increased to 70 (57.4  %) with the addition of rmPCR. Based on sensitivity, incremental yield and more efficient workflow, an algorithm was proposed where lytA and cpsA RT-PCR screening was followed by serotype deduction using rmPCR and a modified set of four instead of eight cmPCRs. This algorithm was validated for use on NP swabs, and the distribution of S. pneumoniae serotypes deduced from this approach showed good concordance with those obtained with cultured isolates serotyped by Quellung and PCR. Overall, molecular detection and serotyping of S. pneumoniae from NP swabs was found to be a valuable tool to assess S. pneumoniae colonization and monitor trends in serotype distribution.
    MeSH term(s) Algorithms ; Bacterial Proteins/genetics ; Humans ; Molecular Diagnostic Techniques/methods ; Multiplex Polymerase Chain Reaction/methods ; N-Acetylmuramoyl-L-alanine Amidase/genetics ; Nasopharynx/microbiology ; Real-Time Polymerase Chain Reaction/methods ; Serogroup ; Streptococcus pneumoniae/classification ; Streptococcus pneumoniae/genetics ; Streptococcus pneumoniae/isolation & purification
    Chemical Substances Bacterial Proteins ; CpsA protein, Streptococcus pneumoniae ; N-Acetylmuramoyl-L-alanine Amidase (EC 3.5.1.28)
    Language English
    Publishing date 2015-06-11
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Validation Study
    ZDB-ID 218356-0
    ISSN 1473-5644 ; 0022-2615
    ISSN (online) 1473-5644
    ISSN 0022-2615
    DOI 10.1099/jmm.0.000097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response.

    Halperin, Scott A / Langley, Joanne M / Ye, Lingyun / MacKinnon-Cameron, Donna / Elsherif, May / Allen, Victoria M / Smith, Bruce / Halperin, Beth A / McNeil, Shelly A / Vanderkooi, Otto G / Dwinnell, Shannon / Wilson, R Douglas / Tapiero, Bruce / Boucher, Marc / Le Saux, Nicole / Gruslin, Andrée / Vaudry, Wendy / Chandra, Sue / Dobson, Simon /
    Money, Deborah

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2018  Volume 67, Issue 7, Page(s) 1063–1071

    Abstract: Background: Immunization of pregnant women with tetanus-diphtheria-acellular pertussis vaccine (Tdap) provides protection against pertussis to the newborn infant.: Methods: In a randomized, controlled, observer-blind, multicenter clinical trial, we ... ...

    Abstract Background: Immunization of pregnant women with tetanus-diphtheria-acellular pertussis vaccine (Tdap) provides protection against pertussis to the newborn infant.
    Methods: In a randomized, controlled, observer-blind, multicenter clinical trial, we measured the safety and immunogenicity of Tdap during pregnancy and the effect on the infant's immune response to primary vaccination at 2, 4, and 6 months and booster vaccination at 12 months of age. A total of 273 women received either Tdap or tetanus-diphtheria (Td) vaccine in the third trimester and provided information for the safety analysis and samples for the immunogenicity analyses; 261 infants provided serum for the immunogenicity analyses.
    Results: Rates of adverse events were similar in both groups. Infants of Tdap recipients had cord blood levels that were 21% higher than maternal levels for pertussis toxoid (PT), 13% higher for filamentous hemagglutinin (FHA), 4% higher for pertactin (PRN), and 7% higher for fimbriae (FIM). These infants had significantly higher PT antibody levels at birth and at 2 months and significantly higher FHA, PRN, and FIM antibodies at birth and 2 and 4 months, but significantly lower PT and FHA antibody levels at 6 and 7 months and significantly lower PRN and FIM antibody levels at 7 months than infants whose mothers received Td. Differences persisted prebooster at 12 months for all antigens and postbooster 1 month later for PT, FHA, and FIM.
    Conclusions: This study demonstrated that Tdap during pregnancy results in higher levels of antibodies early in infancy but lower levels after the primary vaccine series.
    Clinical trials registration: NCT00553228.
    MeSH term(s) Adult ; Antibodies, Bacterial/blood ; Diphtheria/prevention & control ; Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage ; Diphtheria-Tetanus-Pertussis Vaccine/adverse effects ; Diphtheria-Tetanus-Pertussis Vaccine/immunology ; Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage ; Diphtheria-Tetanus-acellular Pertussis Vaccines/adverse effects ; Diphtheria-Tetanus-acellular Pertussis Vaccines/immunology ; Female ; Humans ; Infant, Newborn ; Pregnancy ; Tetanus/prevention & control ; Whooping Cough/prevention & control ; Young Adult
    Chemical Substances Antibodies, Bacterial ; Diphtheria-Tetanus-Pertussis Vaccine ; Diphtheria-Tetanus-acellular Pertussis Vaccines
    Language English
    Publishing date 2018-07-17
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciy244
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Evaluation of the performance of multiple immunoassay diagnostic platforms on the National Microbiology Laboratory SARS-CoV-2 National Serology Panel.

    Dibernardo, Antonia / Toledo, Nikki Pl / Robinson, Alyssia / Osiowy, Carla / Giles, Elizabeth / Day, Jacqueline / Robbin Lindsay, L / Drebot, Michael A / Booth, Timothy F / Pidduck, Tamara / Baily, Ashley / Charlton, Carmen L / Tipples, Graham / Kanji, Jamil N / Brochu, Gino / Lang, Amanda / Therrien, Christian / Bélanger-Collard, Mélina / Beaulac, Sylvie-Nancy /
    Gilfix, Brian M / Boivin, Guy / Hamelin, Marie-Ève / Carbonneau, Julie / Lévesque, Simon / Martin, Philippe / Finzi, Andrés / Gendron-Lepage, Gabrielle / Goyette, Guillaume / Benlarbi, Mehdi / Gasser, Romain / Fortin, Claude / Martel-Lafferrière, Valérie / Lavoie, Myriam / Guérin, Renée / Haraoui, Louis-Patrick / Renaud, Christian / Jenkins, Craig / O'Brien, Sheila F / Drews, Steven J / Conrod, Valerie / Tran, Vanessa / Awrey, Bill / Scheuermann, Robert / DuPuis, Alan / Payne, Anne / Warszycki, Casey / Girardin, Roxie / Lee, William / Zahariadis, George / Jiao, Lei / Needle, Robert / Cordenbach, James / Zaharatos, Jerry / Taylor, Kellee / Teltscher, Marty / Miller, Matthew / Elsherif, May / Robertson, Peter / Robinson, Jason L

    Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada

    2022  Volume 7, Issue 3, Page(s) 186–195

    Abstract: Background: Serological assays designed to detect SARS-CoV-2 antibodies are being used in serological surveys and other specialized applications. As a result, and to ensure that the outcomes of serological testing meet high quality standards, ... ...

    Abstract Background: Serological assays designed to detect SARS-CoV-2 antibodies are being used in serological surveys and other specialized applications. As a result, and to ensure that the outcomes of serological testing meet high quality standards, evaluations are required to assess the performance of these assays and the proficiency of laboratories performing them.
    Methods: A panel of 60 plasma/serum samples from blood donors who had reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections and 21 SARS-CoV-2 negative samples were secured and distributed to interested laboratories within Canada (
    Results: The performance of the different assays evaluated was excellent, with the high-throughput platforms of Roche, Ortho, and Siemens demonstrating 100% sensitivity. Most other high-throughput platforms had sensitivities of >93%, with the exception of the IgG assay using the Abbott ARCHITECT which had an average sensitivity of only 87%. The majority of the high-throughput platforms also demonstrated very good specificities (>97%).
    Conclusion: This proficiency study demonstrates that most of the SARS-CoV-2 serological assays utilized by provincial public health or hospital laboratories in Canada have acceptable sensitivity and excellent specificity.
    Language English
    Publishing date 2022-09-27
    Publishing country Canada
    Document type Journal Article
    ISSN 2371-0888
    ISSN (online) 2371-0888
    DOI 10.3138/jammi-2021-0026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Frailty Hinders Recovery From Acute Respiratory Illness in Older Adults

    Andrew, Melissa K / Lees, Caitlin / Godin, Judith / Black, Karen / McElhaney, Janet / Ambrose, Ardith / Boivin, Guy / Bowie, William R / Elsherif, May / Green, Karen / Halperin, Scott A / Hatchette, Todd / Johnstone, Jennie / Katz, Kevin / Langley, Joanne M / Leblanc, Jason / Lagace-Wiens, Philippe / Loeb, Mark / Mackinnon-Cameron, Donna /
    Mccarthy, Anne / Mcgeer, Allison / Powis, Jeff / Richardson, David / Semret, Makeda / Smith, Stephanie / Smyth, Daniel / Taylor, Geoffrey / Trottier, Sylvie / Valiquette, Louis / Webster, Duncan / Ye, Lingyun / McNeil, Shelly

    Open Forum Infect Dis

    Abstract: BACKGROUND: Influenza vaccination programs aim to prevent serious outcomes. Given that frailty may impact recovery from influenza, we examined frailty as a predictor of recovery in older adults hospitalized with acute respiratory illness. METHODS: Data ... ...

    Abstract BACKGROUND: Influenza vaccination programs aim to prevent serious outcomes. Given that frailty may impact recovery from influenza, we examined frailty as a predictor of recovery in older adults hospitalized with acute respiratory illness. METHODS: Data came from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network during the 2011/12, 2012/13, and 2013/14 influenza seasons; all patients were aged 65+. Frailty was measured using a previously validated Frailty Index (FI) of health and functional deficits; baseline frailty was categorized using published cutoffs (0-.1 non-frail, >.1-.21 pre-frail, >.21-.45 frail, >.45 most frail). Recovery was operationalized as being alive 30 days post-discharge with less than two additional health/functional deficits (<=0.06 FI increase). Logistic regression was used to examine the change in odds of recovery for every 0.1 increase in baseline FI, controlling for age, sex, season, lab-confirmed influenza status, and seasonal influenza vaccination status. RESULTS: Of 5125 hospitalized older adults, 15% were non-frail, 39% pre-frail, 40% frail, and 6% most frail. 11% died, and poor recovery was experienced by 520/4544=11% of survivors. Poor recovery was inversely associated with baseline frailty (11% non-frail, 17% pre-frail, 28% frail, 38% most frail; P < .001). Frailty was associated with lower odds of recovery in all three seasons [2011/12 (OR=0.71; 95% CI 0.60–0.85), 2012/13 (OR=0.72; 0.66–0.78), 2013/14 (OR=0.76; 0.70–0.82)] though results varied by season, influenza status, and vaccination status. In 2011/12, frailty was associated with poor recovery in unvaccinated (OR=0.46. 95% CI=0.32–0.67) but not vaccinated older patients (OR=0.83, 95% CI=0.68–1.02). CONCLUSION: Increasing frailty was consistently associated with lower odds of recovery in older adults admitted with influenza and other acute respiratory illnesses; depending on seasonal factors, vaccination may offer some buffering of this impact. Understanding frailty and functional status is important, both because frailty is predictive of poor recovery and because persistence of new health/functional deficits is an adverse outcome with important implications for patients, families and health systems. DISCLOSURES: M. K. Andrew, GSK: Grant Investigator, Research grant; Pfizer: Grant Investigator, Research grant; Sanofi-Pasteur: Grant Investigator, Research grant; J. McElhaney, GSK Vaccines: Scientific Advisor, Speaker honorarium; M. Elsherif, Canadian Institutes of Health Research: Investigator, Research grant; Public Health Agency of Canada: Investigator, Research grant; GSK: Investigator, Research grant; S. A. Halperin, GSK: Scientific Advisor, Consulting fee; GSK: Grant Investigator, Research grant; T. Hatchette, GSK: Grant Investigator, Grant recipient; Pfizer: Grant Investigator, Grant recipient; Abbvie: Speaker for a talk on biologics and risk of TB reactivation, Speaker honorarium; J. M. Langley, GSK: Investigator, Research grant; Canadian Institutes of Health Research: Investigator, Research grant; A. Mcgeer, Hoffman La Roche: Investigator, Research grant; GSK: Investigator, Research grant; sanofi pasteur: Investigator, Research grant; J. Powis, Merck: Grant Investigator, Research grant; GSK: Grant Investigator, Research grant; Roche: Grant Investigator, Research grant; Synthetic Biologicals: Investigator, Research grant; M. Semret, GSK: Investigator, Research grant; Pfizer: Investigator, Research grant; S. Trottier, Canadian Institutes of Health Research: Investigator, Research grant; L. Valiquette, GSK: Investigator, Research grant; S. McNeil, GSK: Contract Clinical Trials and Grant Investigator, Research grant; Merck: Contract Clinical Trials and Speaker’s Bureau, Speaker honorarium; Novartis: Contract Clinical Trials, No personal renumeration; sanofi pasteur: Contract Clinical Trials, No personal renumeration
    Keywords covid19
    Publisher PMC
    Document type Article ; Online
    DOI 10.1093/ofid/ofx163.1500
    Database COVID19

    Kategorien

To top